🇺🇸 FDA
Patent

US 11718679

CD137 antibodies and PD-1 antagonists and uses thereof

granted A61KA61K2039/507A61K39/001111

Quick answer

US patent 11718679 (CD137 antibodies and PD-1 antagonists and uses thereof) held by Compass Therapeutics LLC expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Compass Therapeutics LLC
Grant date
Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2039/507, A61K39/001111, A61K39/001117, A61P